All lobbying filings
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Lobbying for NOVARTIS · Multinational biopharmaceutical company
Filing · LD-2 quarterly report
Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$90,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
1
-
JOHN REISING New on this filingPreviously held: Scheduler, Operations Director, Member Services Director, Deputy Chief of Staff- Majority Leader Steve Scalise; Operations Director, Rep. Bill Flores; Scheduler, Rep. Austin Scott; Intern, Senator Trent Lott.
Government bodies contacted
2
Lobbying activity
1
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Bills named in this filing
1
Foreign interests disclosed
1
-
NOVARTIS INTERNATIONAL AGSwitzerland · CH-4056 Basel · owns 100% of the client · contributed $0